Evidence map›Paper›PMID 37420019›Full record

SynthesisEuropean journal of clinical pharmacology2023

Proton pump inhibitor use: systematic review of global trends and practices.

Lelwala Guruge Thushani Shanika, Andrew Reynolds, Sharon Pattison, Rhiannon Braund

Registry-linked trialOpen access · hybridAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European journal of clinical pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06858384 (From Awareness to Action), which is not on this map. Cited by 125 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 8 pooled it
53.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06858384 narecruitingnot on this mapstarted 2025, after this paper: background citation

From Awareness to Action: Transforming Proton Pump Inhibitor Use in Ras Al Khaimah Through Education and Intervention: the RAK -PRIDE Study

TypeinterventionalSponsorRAK Medical and Health Sciences UniversityRan2025 to 2026Enrolled479ConditionsProton Pump Inhibitors, Deprescribing, Inappropriate UseArmsControl (Standard treatment), Pharmacist-Led Educational Intervention
3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 8 syntheses or guidelines pooled it, 187 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Randomized controlled trial of an oral gastrin receptor antagonist for the treatment of postmenopausal osteoporosis.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Observational
  20. Article

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Lelwala Guruge Thushani ShanikaNew Zealand Pharmacovigilance Centre, University of Otago, 913, Dunedin, 9054, New Zealand.
Andrew ReynoldsDepartment of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
Sharon PattisonDepartment of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
Rhiannon BraundNew Zealand Pharmacovigilance Centre, University of Otago, 913, Dunedin, 9054, New Zealand. rhiannon.braund@otago.ac.nz.
University of Otago · NZUniversity of Sri Jayewardenepura · LK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeProton pump inhibitors (PPIs) reduce acid secretion in the stomach and rank as one of the most widely used acid-suppressing medicines globally. While PPIs are safe in the short-term, emerging evidence shows risks associated with long-term use. Current evidence on global PPI use is scarce. This systematic review aims to evaluate global PPI use in the general population.

methodsOvid MEDLINE, Embase, and International Pharmaceutical Abstracts were systematically searched from inception to 31 March 2023 to identify observational studies on oral PPI use among individuals aged ≥ 18 years. PPI use was classified by demographics and medication factors (dose, duration, and PPI types). The absolute numbers of PPI users for each subcategory were summed and expressed as a percentage.

resultsThe search identified data from 28 million PPI users in 23 countries from 65 articles. This review indicated that nearly one-quarter of adults use a PPI. Of those using PPIs, 63% were less than 65 years. 56% of PPI users were female, and "White" ethnicities accounted for 75% of users. Nearly two-thirds of users were on high doses (≥ defined daily dose (DDD)), 25% of users continued PPIs for > 1 year, and 28% of these continued for > 3 years.

conclusionGiven the widespread use PPIs and increasing concern regarding long-term use, this review provides a catalyst to support more rational use, particularly with unnecessary prolonged continuation. Clinicians should review PPI prescriptions regularly and deprescribe when there is no appropriate ongoing indication or evidence of benefit to reduce health harm and treatment cost.

Indexed as

Proton Pump InhibitorsUpper Gastrointestinal TractAdultFemaleHealth Care CostsHumansMalePrescriptionsProton Pump InhibitorsDoseGlobal useLong termProton pump inhibitorsSystematic review

Identifiers

PMID37420019
PMCPMC10427555
OpenAlexW4383500880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.